A clinical trial on the early detection and correction of haemostatic defects in selected high-risk neonates

Area of Science:

• Neonatal Medicine
• Hematology

Background:

• Neonatal populations, including low birth weight, preterm infants with respiratory distress syndrome, and term infants with birth asphyxia, are susceptible to coagulation disorders.
• Early identification and management of hemostatic defects are crucial in these vulnerable infants.

Purpose of the Study:

• To screen and assess coagulation abnormalities in at-risk newborn infants.
• To evaluate the efficacy and safety of blood product transfusion in correcting hemostatic defects.

Main Methods:

• Newborns with low birth weight, respiratory distress syndrome, or asphyxia underwent screening for coagulation abnormalities shortly after birth.
• Infants with identified hemostatic defects were assigned to control or treatment groups.
• Treatment involved administration of prothrombin complex concentrate, cryoprecipitate, or platelet concentrate as indicated.

Main Results:

• Treatment effectively corrected the identified hemostatic defects in the majority of infants.
• No significant changes in mortality rates were observed between the treatment and control groups.
• No adverse or beneficial side-effects of the applied treatments were detected.

Conclusions:

• Blood product transfusion is effective in managing coagulation abnormalities in at-risk newborns.
• Current treatment strategies for neonatal hemostatic defects do not appear to influence mortality outcomes.
• Further research may be warranted to explore potential long-term effects or alternative interventions.